硫酸阿米卡星/磷霉素钠(Amikacin Sulfate/Fosfomycin sodium) - 药物靶点：30S subunit_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

30S subunit

作用机制

30S subunit抑制剂(30S核糖体亚基抑制剂)

治疗领域

感染呼吸系统疾病

在研适应症-

非在研适应症

革兰氏阴性菌肺炎

原研机构

Cardeas Pharma Corp.

在研机构-

非在研机构

Cardeas Pharma Corp.

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C3H7NaO4P

InChIKeyBLLKJRKIOJQXCC-LJUKVTEVSA-N

CAS号26016-99-9

查看全部结构式(3)

关联

3

项与硫酸阿米卡星/磷霉素钠相关的临床试验

NCT02709265 / Completed临床1期

An Open-Label Phase 1 Study of Aerosolized Amikacin and Fosfomycin Delivered Via the PARI Investigational eFlow Nebulizer System or the PARI LC Sprint Nebulizer in Healthy Volunteers

This study will evaluate systemic and urine pharmacokinetics in spontaneously breathing healthy volunteers following a single dose of amikacin/fosfomycin, using the PARI Investigational eFlow Nebulizer System or the PARI LC Sprint Nebulizer. Three doses (30/12 mg, 60/24 mg, 90/36 mg amikacin/fosfomycin) will be evaluated. Following this evaluation, a single dose and nebulizer will be chosen to further evaluate systemic, bronchoalveolar, and urine pharmacokinetics in spontaneously breathing healthy volunteers.

开始日期2016-04-01

申办/合作机构

Cardeas Pharma Corp.

NCT02218359 / Withdrawn临床2期

A Randomized Double-Blind, Placebo-Controlled, Crossover to Open Label, Phase 2 Study of Aerosolized Amikacin and Fosfomycin Delivered Via the Investigational eFlow® AFIS Inline System in Mechanically Ventilated Patients With Gram-negative and/or Gram-positive Bacterial Colonization

To demonstrate the safety and efficacy of adjunctive therapy with the Amikacin Fosfomycin Inhalation System (AFIS) versus aerosolized placebo in mechanically ventilated patients with Gram-negative and / or Gram-positive bacterial colonization.

开始日期2014-10-01

申办/合作机构

Cardeas Pharma Corp.

NCT01969799 / Completed临床2期

A Randomized Blinded, Placebo-Controlled, Phase 2 Study of Aerosolized Amikacin and Fosfomycin Delivered Via the Investigational eFlow® Inline System in Mechanically Ventilated Patients With Gram-negative Bacterial Pneumonia (IASIS)

To demonstrate the safety and efficacy of adjunctive therapy with the Amikacin fosfomycin inhalation system (AFIS) versus aerosolized placebo to treat Gram-negative pneumonia in mechanically ventilated patients receiving IV antibiotics.

开始日期2013-12-01

申办/合作机构

Cardeas Pharma Corp.

100 项与硫酸阿米卡星/磷霉素钠相关的临床结果

登录后查看更多信息

100 项与硫酸阿米卡星/磷霉素钠相关的转化医学

登录后查看更多信息

100 项与硫酸阿米卡星/磷霉素钠相关的专利（医药）

登录后查看更多信息

100 项与硫酸阿米卡星/磷霉素钠相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
革兰氏阴性菌肺炎	临床2期	希腊	Cardeas Pharma Corp.	2013-12-01
革兰氏阴性菌肺炎	临床2期	法国	Cardeas Pharma Corp.	2013-12-01
革兰氏阴性菌肺炎	临床2期	土耳其	Cardeas Pharma Corp.	2013-12-01
革兰氏阴性菌肺炎	临床2期	匈牙利	Cardeas Pharma Corp.	2013-12-01
革兰氏阴性菌肺炎	临床2期	西班牙	Cardeas Pharma Corp.	2013-12-01
革兰氏阴性菌肺炎	临床2期	波多黎各	Cardeas Pharma Corp.	2013-12-01
革兰氏阴性菌肺炎	临床2期	美国	Cardeas Pharma Corp.	2013-12-01